CENTOGENE N.V. (CNTG): Price and Financial Metrics


CENTOGENE N.V. (CNTG)

Today's Latest Price: $12.20 USD

0.34 (-2.71%)

Updated Dec 1 4:00pm

Add CNTG to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 58 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

CNTG Stock Summary

  • With a one year PEG ratio of 0.51, Centogene NV is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than merely 6.17% of US stocks.
  • Centogene NV's stock had its IPO on November 7, 2019, making it an older stock than only 0.56% of US equities in our set.
  • In terms of twelve month growth in earnings before interest and taxes, Centogene NV is reporting a growth rate of 79.01%; that's higher than 86.08% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Centogene NV are QUOT, XENT, EB, VIVE, and KALA.
  • CNTG's SEC filings can be seen here. And to visit Centogene NV's official web site, go to www.centogene.com.

CNTG Stock Price Chart Interactive Chart >

Price chart for CNTG

CNTG Price/Volume Stats

Current price $12.20 52-week high $28.71
Prev. close $12.54 52-week low $7.80
Day low $12.01 Volume 58,800
Day high $12.80 Avg. volume 95,178
50-day MA $11.13 Dividend yield N/A
200-day MA $14.83 Market Cap 242.30M

CENTOGENE N.V. (CNTG) Company Bio


Centogene NV is a commercial-stage company. It focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. It operates through the following two segments: Pharmaceutical and Diagnostics. The Pharmaceutical segment provides services to pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery and patient monitoring. The Diagnostics segment provides targeted genetic sequencing and diagnostics services. The company was founded by Arndt Rolf and Christoph Ehlers in 2006 and is headquartered in Rostock, Denmark.


CNTG Latest News Stream


Event/Time News Detail
Loading, please wait...

CNTG Latest Social Stream


Loading social stream, please wait...

View Full CNTG Social Stream

Latest CNTG News From Around the Web

Below are the latest news stories about Centogene NV that investors may wish to consider to help them evaluate CNTG as an investment opportunity.

FDA OKs emergency use of Centogene molecular coronavirus test

The FDA grants emergency use authorization to Centogene's ([[CNTG]] +0.5%) SARS-CoV-2 RT PCR (real-time polymerase chain reaction) assay that qualitatively (yes/no answer) detects genetic material from the coronavirus in oropharyngeal swab specimens.Testing is limited to CLIA-certified labs....

Seeking Alpha | October 1, 2020

Centogene reports Q2 results

Centogene (CNTG): Q2 GAAP EPS of -€0.52.Revenue of €9.7M (-13.5% Y/Y)Shares +1% PM.Press Release...

Seeking Alpha | September 23, 2020

CENTOGENE and Molecular Health Announce an Exclusive Collaboration With the Aim to Transform the Development of Orphan Drugs

* The combination of real-life data sets in rare diseases with innovative big data/artificial intelligence/novel scientific computational knowledge will transform biomedical research, product development, and therapy. * Real-life data and Innovative Bioinformatic Algorithms (RIBA project) will enable the creation of a powerful environment to accelerate, de-risk, and improve the development of new orphan drugs for many diseases and disease areas. * RIBA develops and offers data-/computing-driven solutions to guide the highest and most precise innovation for a new way of drug development in a modern biopharmaceutical environment. * The collaboration will start with Epilepsy as the first indicationCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN and HEIDELBERG, Germany, July 27, 2020 (G...

Yahoo | July 27, 2020

CENTOGENE Announces Convenient At-Home Coronavirus Test Solution Now Available in Germany on Online Marketplace

CENTOGENE announces test kits for the detection of SARS-CoV-2 virus RNA now available on Amazon in Germany ─ the first of its type offered on the online…

GlobeNewswire | July 23, 2020

CENTOGENE Announces the Scientific Publication of a holistic solution in the preventive testing of COVID-19

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 09, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage diagnostics and…

GlobeNewswire | July 9, 2020

Read More 'CNTG' Stories Here

CNTG Price Returns

1-mo 9.81%
3-mo 10.61%
6-mo -36.98%
1-year 0.00%
3-year N/A
5-year N/A
YTD 21.15%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7082 seconds.